Sopherion Therapeutics

company

About

Sopherion has the US and Canadian rights to this liposomal nanotechnology that targets the tumor vasculature.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$47M
Industries
Biotechnology,Health Care,Health Diagnostics,Pharmaceutical
Founded date
Jan 1, 2001
Number Of Employee
11 - 50
Operating Status
Active

Sopherion Therapeutics, LLC is a privately held biopharmaceutical company headquartered in Princeton, New Jersey with offices in Cheshire, Connecticut, Estero, Florida and an operating subsidiary, Sopherion Therapeutics Canada, in Toronto, Canada.

Sopherion Therapeutics LLC is a specialty biopharmaceutical company with an exclusive licensing agreement with Zeneus Pharma Ltd., now Cephalon, Inc., for the commercialization of Myocet™ (a liposome-encapsulated doxorubicin-citrate complex) in the United States and Canada. Sopherion’s current business focus is the execution of a Phase III, global, randomized, registration trial for first line therapy of invasive, metastatic breast cancer and the development and commercialization of Sopherion’s lead agent, Myocet™. Myocet is being investigated in an FDA agreed upon registration trial in combination with two other drugs, Herceptin® (Trastuzumab) and Taxol (Paclitaxel) vs. Herceptin® and Taxol alone, the current standard of care for first line HER-2-overexpressing metastatic breast cancer. Myocet™, a liposome-encapsulated doxorubicin with reduced cardiotoxicity, is a nanotechnology product that localizes into tumor vasculature and in contrast to parental doxorubicin avoids homing to the heart. This 363 patient global trial in twelve countries has as of 03/06/09 been fully recruited. Unblinding is anticipated by the summer of 2010 with NDA submission for full approval following within 6 months. Myocet® is already a registered drug in Canada, where Sopherion has commercial rights and in Europe where Cephalon has commercial rights for use in first line metastatic breast cancer in combination with cyclophosphamide.; Their Phase III trial is based on a Phase II trial, supported by Roche, which gave a 96% response rate and two and a half year median progression free survival for patients with metastatic breast cancer.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$163M
Sopherion Therapeutics has raised a total of $163M in funding over 2 rounds. Their latest funding was raised on Feb 19, 2009 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 19, 2009 Series C $55M 1 Zoticon BioVentures Detail
Jan 1, 2008 Series Unknown $35M 1 Zoticon BioVentures Detail
Sep 24, 2004 Series B $47M 2 Detail
Mar 10, 2003 Series A $26M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
4
Sopherion Therapeutics is funded by 4 investors. Zoticon BioVentures and Commerce Health Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Zoticon BioVentures Yes Series C
Commerce Health Ventures Series B
Seaflower Ventures Series B
GE Capital Life Science and Technology Finance Series A